Results 121 to 130 of about 21,178 (234)

DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus. [PDF]

Diabetes Metab Syndr Obes
Shao Y, Chen Y, Zhu M, Liu Y, Fang C, Wang M, Sun P, Fu W, Huang J, Sheng S, Huang Y.   +10 more
europepmc   +1 more source

The Neuroprotective Potentials of Dual GIP/GLP1‐RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review

Brain and Behavior, Volume 16, Issue 8, August 2026.
The graphical abstract summarizes the current evidence on the potential neuroprotective effects of tirzepatide (TZP), a dual GIP/GLP‐1 receptor agonist, across mechanistic, preclinical, and clinical domains. Mechanistically, TZP is proposed to exert direct neural effects, preserve mitochondrial function, reduce apoptosis, oxidative stress, and ...
Yousef Hawas, Mohamed Abouzid, Ahmed Farid Gadelmawla, Dalia Kamal Ewis, Abdallah Khatatbeh, Yasmin Negida, Ahmed Negida   +6 more
wiley   +1 more source

Mitochondrial Mediated Apoptosis Evaluation of Myristicin on Triple Negative Breast Cancer Model Via Bcl2/Bid Pathway

Cell Biochemistry and Function, Volume 44, Issue 8, August 2026.
ABSTRACT Among 15‐20 cases of breast cancer, triple‐negative breast cancer (TNBC) is the deadliest form of the disease. The most effective form of treatment for this type of cancer is still targeted chemotherapy because it lacks hormone receptors. Myristicin, an active aromatic compound with anticancer properties, is mostly found in nutmeg.
Sudhina Sufina Nazar, Aswathy Vadakkumkattle Ajaykumar, Janeesh Plakkal Ayyappan   +2 more
wiley   +1 more source

Sensory and motor physiological functions are impaired in gastric inhibitory polypeptide receptor-deficient mice. [PDF]

J Diabetes Investig, 2014
Okawa T, Kamiya H, Himeno T, Seino Y, Tsunekawa S, Hayashi Y, Harada N, Yamada Y, Inagaki N, Seino Y, Oiso Y, Nakamura J.   +11 more
europepmc   +1 more source

The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon‐Like Peptide‐1‐Based Therapies

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8735-8739, September 2026.
Rune Viig Overgaard, Henrik Agersø, Christian Hollensen, Naveen Rathor, Eric M. Bomberg   +4 more
wiley   +1 more source

ETS1–EGR2 facilitates renal cell carcinoma progression by activating NOTCH signalling

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
ETS1 expression is significantly higher in ccRCC samples, and ETS1‐overexpression increases RCC cell malignancies in vitro and tumour growth in nude mice. ETS1 binds to EGR2 and destabilises EGR2 protein, which relieves EGR2's inhibitory effect on NOTCH signalling. NOTCH signalling activation promotes RCC development.
Weifeng Ye, Sishun Gan, Qiang Xu, Xiaoyang Shu, Panpan Dong, Lin Li, Chao Tang   +6 more
wiley   +1 more source

Enhancing Optogenetics‐Based Cancer Therapy Via Nanotechnology

Exploration, Volume 6, Issue 4, August 2026.
Nanotechnology enhances optogenetics‐based cancer therapy through improved delivery systems and non‐invasive optical regulation. It further enables precise and programmable control of optogenetic living therapeutics for localized antitumor responses.
Honggang Shen, Wenzhe Yi, Rongzhang Li, Shuangshuang Hu, Xindi Qian, Dan Yan, Qian Zou, Guanru Wang, Yaping Li   +8 more
wiley   +1 more source

Cod Skin Collagen Peptides Alleviate Ulcerative Colitis by Regulating Gut Microbiota to Inhibit NLRP3 Inflammasome Activation

Food Science &Nutrition, Volume 14, Issue 8, August 2026.
CP suppresses NLRP3 inflammasome activation through modulation of the gut microbiota, thereby exerting protective effects against ulcerative colitis. ABSTRACT Enteral nutrition is an important intervention for ulcerative colitis, and collagen can improve immune responses and repair the intestinal barrier.
Longyi Piao, Jiaqi Huo, Yanru Dong, Shuxia Cao, Xiangdan Li, Dongyuan Xu, Xianglan Li, Lan Liu   +7 more
wiley   +1 more source

Beyond Weight Loss: Tirzepatide as a Metabolic Disease‐Modifying Strategy for Metabolic Dysfunction‐Associated Steatohepatitis: A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide and a major contributor to liver‐related morbidity and mortality. Its progressive subtype, metabolic dysfunction–associated steatohepatitis (MASH), is characterized by hepatocellular injury, inflammation,
Zubaier Ahmed, Nashrah Mustafa, Tamanna Sarkar, Hasina Yasmin   +3 more
wiley   +1 more source

Long‐Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Long‐acting (LA) antiretroviral (ARV) medications represent a significant advancement in the HIV treatment and prevention field. LA ARVs help reduce daily pill burden and thus optimize adherence, which has translated into sustained virologic suppression in persons with HIV, prevention of HIV transmission among those at risk, and improved ...
Alexandra Dunbar, Natella Rakhmanina, Justin Unternaher, Peter L. Anderson, Kristina M. Brooks   +4 more
wiley   +1 more source